

10 Jan 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis's Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio's Phase III failure; and a look at gene editing companies to watch at JP Morgan.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 January 2022, including: new mRNA deal for [*Pfizer Inc.*](#) and [*BioNTech SE*](#); court ruling helps [*Novartis AG*](#)'s Gilenya; first cut-price generic Paxlovid launched; breaking down [*BridgeBio Pharma, Inc.*](#)'s Phase III failure; and a look at gene editing companies to watch at JP Morgan.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA*](#)" - Scrip, 5 Jan, 2022.)

(Also see "[*Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge*](#)" - Scrip, 4 Jan, 2022.)

(Also see "[*Beximco Delivers First Cut-Price Generic Paxlovid*](#)" - Scrip, 31 Dec, 2021.)

(Also see "[*Stock Watch: Bridgebio's Endpoint A Bridge Too Far*](#)" - Scrip, 3 Jan, 2022.)

(Also see "[*Gene-Editing Companies To Watch At J.P. Morgan*](#)" - Scrip, 5 Jan, 2022.)

[*Click here to explore this interactive content online*](#) ✨